TuHURA Biosciences, Inc. Common Stock (HURA) is a publicly traded Healthcare sector company. As of May 21, 2026, HURA trades at $2.41 with a market cap of $162.39M and a P/E ratio of -3.82. HURA moved -3.25% today. Year to date, HURA is +225.08%; over the trailing twelve months it is -35.75%. Its 52-week range spans $0.41 to $7.93. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces HURA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
TuHURA Biosciences Reports Q1 Results, Secures $50M Facility to 2028: TuHURA Biosciences secured a $50 million credit facility bearing 12% interest, extending its cash runway into 2028 and maintaining $6.3 million in cash as of March 31, 2026. The company reported Q1 R&D expenses of $5.2 million and net operating cash outflows of $4.4 million, while advancing its Phase 3 IFx-2.0 trial and targeting FDA meetings for its VISTA inhibitor TBS-2025.
| Metric | Value |
|---|---|
| Price | $2.41 |
| Market Cap | $162.39M |
| P/E Ratio | -3.82 |
| EPS | $-0.63 |
| Dividend Yield | 0.00% |
| 52-Week High | $7.93 |
| 52-Week Low | $0.41 |
| Volume | 564.89K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-30.05M |
| Gross Margin | 0.00% |
3 analysts cover HURA: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.